One-page list of most allergists in the US, by the American Board of Allergy and Immunology (ABAI)

One-page list of most allergists in the US, by the American Board of Allergy and Immunology. The following physicians are currently reported as Meeting Maintenance of Certification (MOC) Requirements:

https://www.abai.org/DipMOC.asp

Allergists who board-certified more than 10 years ago (or so) and don't have to participate in MOC may not be listed. They are in the "grandfathered-in" group. Please note that participation in the ABAI MOC program is voluntary for diplomates with time-unlimited certificates.

The 12 Best Asthma Blogs of 2016 - according to Healthline - we made the list at number 3

The 12 Best Asthma Blogs of 2016 - according to Healthline: "We’ve carefully selected these blogs because they are actively working to educate, inspire, and empower their readers with frequent updates and high quality information."

http://buff.ly/1U1y8s6

We made the list at number 3.

May 2nd is Now "Bronchial Thermoplasty Awareness Day" in Pennsylvania

Asthma is a disease that causes the airways of the lungs to swell and narrow, leading to wheeze, shortness of breath, chest tightness, and cough. Asthma is the most common chronic lung disease, affecting up to 10% of adults and 30% of children. Bronchial Thermoplasty (BT) is one of the treatment options for severe asthma - see below:



Asthma Treatment Options in 6 Steps (click to enlarge the image).

May 2nd is Now "Bronchial Thermoplasty Awareness Day" in Pennsylvania. From the manufacturer's YouTube channel: Bronchial Thermoplasty Day in Pennsylvania:



Here is how the procedure looks like, again from the manufacturer's channel:

Proton pump inhibitors are first-line treatment for EoE, achieving improvement of symptoms in 60% of patients

There are various therapeutic options available for treating patients with eosinophilic esophagitis (EoE):

- dietary modifications
- proton pump inhibitors (PPI)
- topical corticosteroids
- endoscopic esophageal dilation

Proton pump inhibitors are currently considered the first-line treatment for eosinophilic esophagitis, achieving histological remission and improvement of symptoms in 50.5% and 60.8% of patients, respectively.

Regarding topical corticosteroids in eosinophilic esophagitis, budesonide and fluticasone propionate both decrease eosinophil densities in the esophageal mucosa and relieve symptoms. However, owing to differences in drug delivery, viscous budesonide seems to be the best pharmacological therapy for eosinophilic esophagitis.

Results for dietary modifications have been mixed depending on the type of diet prescribed:

- amino acid-based elemental diets are the most effective in inducing histological remission of eosinophilic esophagitis (90.8% but they have drawbacks limiting implementation in clinical practice

- allergy testing-based food elimination provides a suboptimal remission rate of 45.5%, although this is lower in adults than in children (32.2% vs 47.9%, respectively)

- empirical 6-food elimination diets were shown to be the best diet-based therapy, with a remission rate of 72%



Eosinophilic Esophagitis (click here to enlarge the image).



References:

Eosinophilic Esophagitis: An Evidence-Based Approach to Therapy. González-Cervera J, Lucendo AJ. J Investig Allergol Clin Immunol. 2016;26(1):8-18; quiz 2p following 18.
http://www.ncbi.nlm.nih.gov/pubmed/27012011?dopt=Abstract

Image source: Eosinophilic esophagitis, Wikipedia, GNU Free Documentation License.

Improvements in impulse oscillometry after chronic dosing with formoterol compared with salmeterol might reflect better deposition to small airways

Effects of small-particle long-acting beta-agonists on the small airways have been poorly documented. This study used impulse oscillometry (IOS) to compare single and repeated dosing effects of small- (formoterol MDI) and large-particle (salmeterol DPI) long-acting beta-agonists.

16 patients received either formoterol or salmeterol twice daily plus inhaled corticosteroid for 1 to 2 weeks with a 1- to 2-week washout period in between (mean age, 43 years; FEV1, 80%, FEF25-75, 48%).

There were greater improvements with formoterol versus salmeterol in all IOS outcomes but not FEV1.

Significant improvements in IOS outcomes but not spirometry results occurred after chronic dosing with formoterol compared with salmeterol. This might reflect better deposition to the entire lung, including the small airways.

References:

Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma. Arvind Manoharan et al. JACI, March 2016, Volume 137, Issue 3, Pages 727–733.e1.
http://www.jacionline.org/article/S0091-6749(15)00861-1/abstract

Image source: Lungs, Wikipedia, public domain.
Blog Widget by LinkWithin